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Abstract
Background: It has been previously suggested that angiogenesis occurs during the menstrual cycle. Moreover, a
rise in uterine blood flow is largely maintained by vasodilatation and substantial increases in angiogenesis. It is
known that estradiol (E2) and progesterone (P4) are involved in angiogenesis. Recently, endothelial progenitor cells
(EPCs) were found to be involved in neovascularization; however, their roles in uterine neovascularization have not
been well characterized. We hypothesized that E2- or P4-mediated EPC proliferation plays important roles in
uterine neovascularization during the menstrual cycle.
Methods: The number of EPCs in peripheral blood from subjects in the menstrual phase (n = 12), follicular phase
(n = 8), and luteal phase (n = 16), was measured using flow cytometry. Peripheral blood mononuclear cells
(PBMCs) were cultured for seven days with or without 17beta-estradiol (E2beta) or P4, followed by assessment of
EPC proliferation based upon the uptake of acetylated low density lipoprotein (LDL) and lectin. The expression of
estrogen receptor (ER) or progesterone receptor (PR) in EPCs was also evaluated using real-time PCR.
Results: E2beta and P4 significantly increased the proliferation of EPCs derived from the peripheral blood of
subjects in menstrual phase, but not subjects in the luteal phase. In addition, the expression level of ERalpha was
markedly higher than ERbeta in EPCs derived from women in menstrual phase.
Conclusions: EPC proliferation is induced during the menstrual phase and proliferation can be affected by
estrogen through ERalpha activation.
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Background
Angiogenesis in female reproductive organs, including
the uterus, corpus luteum, and placenta, is essential for
implantation and is critical for the dramatic (30-50 fold)
elevation of uterine blood flow during pregnancy [1,2].
Disturbances in uterine vascular development are asso-
ciated with pregnancy loss, preeclampsia, and intrauter-
ine growth restriction [3]. Periodic uterine endometrial
neovascularization begins after menstruation and con-
tinues into the luteal phase [4]. In general, it is thought
that neovascularization is mainly caused by angiogenesis,
which is the sprouting of capillaries from pre-existing
vessels, such as in tumors and embryos. However, vas-
culogenesis, which is mediated by endothelial progenitor
cells (EPCs), has recently been proposed to be involved
in endometrial neovascularization [5,6]. The presence of
EPCs in peripheral blood provides a maintenance reser-
voir of endothelial cells (ECs) and contributes to up to
25% of ECs in newly formed vessels [7]. It has been
hypothesized that EPCs may be involved in the growth
of the uterine endometrium since EPCs localize within
the vasculature and stroma of the uterine endometrium
and myometrium after ovulation [8].
In female reproductive organs, neovascularization may
be partially regulated by cyclic changes in sex steroids,
such as estradiol (E2) and progesterone (P4) [9,10] in
response to the hormones produced by the hypothala-
mus, pituitary gland, and ovaries [11]. Serum E2 and P4
concentrations are very low during the early follicular
phase [12]. During this phase, serum estrogen levels rise
in parallel to the growth of follicle size and granulosa
cells. Before ovulation, follicle-produced E2 is increased
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and luteinization of the granulosa cells is stimulated,
which leads to the synthesis of P4. After ovulation, the
granulosa cells continue to enlarge and become lutein.
The corpus luteum, which consists of luteinized granu-
losa cells and theca-lutein cells, secretes P4. There is a
secondary rise in E2 levels during the mid-luteal phase
following a decrease before menstruation, and this rise
in E2 levels occurs in parallel with the rise of serum P4
levels. However, the effects of these hormones and their
interactions in reproductive organs remain unclear,
especially in vasculogenesis.
Estrogen receptors (ERs) are expressed in uterine
arterial ECs [13,14], as well as in other types of ECs
[15], which suggests that 17b-estradiol (E2b) can act
directly on the cells and alter uterine vascular function.
It has been reported that E2b can enhance angiogenesis
[16,17] and vasculogenesis by increasing the number of
EPCs [18]. These data support the theory that E2b is an
important factor in promoting neovascularization in
female reproductive organs. Similar to E2b, P4 has also
been shown to influence uterine angiogenesis [19]. P4
may enhance E2b-induced angiogenesis by increasing
endothelial nitric oxide synthase (eNOS) expression
[20]. In contrast, it has been reported that P4 inhibits
E2b-reduced neointimal proliferation [21] and decreases
ER and P4 receptor (PR) expression in human uterine
vascular endothelium [22], which consequently attenu-
ates E2b-induced angiogenic responses [23,24].
The aim of this study was to evaluate the influence of
sex steroids on the proliferation of EPCs during the
menstrual cycle. The findings of this study could help




This study was approved by the Ehime University Insti-
tutional Review Board. All participants gave informed
consent for participation in this study. Peripheral venous
blood (20 ml) from healthy young volunteers in the
menstrual phase (n = 12; 30 ± 4 years-old), follicular
phase (n = 8; 30 ± 5 years-old), luteal phase (n = 16; 28
± 4 years-old) with regular menstrual cycles (24-35 d)
was collected in tubes containing sodium heparin. The
menstrual cycle dates were determined by measuring
the basal body temperature (BBT) as reported by the
patient and serum E2 (follicular phase > 10 pg/ml) and
progesterone (follicular phase < 1.5 ng/ml; luteal phase
> 5.7 ng/ml) concentrations. The follicular phase is
characterized by a lower BBT [11]. Peripheral blood
mononuclear cells (PBMCs) were isolated by density
gradient centrifugation at 1600 rpm for 60 min with
Ficoll-Paque separating solution (Amersham Pharmacia
Biotech; AB, Uppsala, Sweden). The PBMC layer was
collected, cells were counted, and then a fraction of the
cells was resuspended in Dulbecco’s phosphate-buffered
saline (D-PBS: Invitrogen; Carlsbad, CA) with 1% fetal
bovine serum (FBS: Invitrogen) for fluorescence-acti-
vated cell sorting (FACS) analysis. Circulating EPCs
(cEPCs) were characterized by the expression of vascular
endothelial growth factor receptor 2 (VEGF-R2; kinase
domain receptor [KDR]), AC133, and CD34 on the sur-
face of PBMCs.
To assess the proliferation of EPCs, the cells were culti-
vated according to a previously described technique [25].
Briefly, PBMCs (8 × 105 cells) were seeded into each well
of 96-well culture plates coated with human fibronectin
(Sigma-Aldrich, St. Louis, MO) and cultured in endothe-
lial basal medium-2 (EBM-2, Clonetics; San Diego, CA)
supplemented with EGM-2MV (Clonetics) consisting of
5% FBS, VEGF, fibroblast growth factor-2 (FGF2), epider-
mal growth factor (EGF), insulin-like growth factor-1
(IGF1), and ascorbic acid. After four days in culture, non-
adherent cells were removed and adherent cells were
subsequently cultured for an additional three days.
Low density lipoprotein (LDL)/lectin assay
After seven days in culture, adherent cells were assessed
as EPCs based on the uptake of 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindocarbocyanine-labeled acetylated LDL
(Dil-Ac-LDL, Biogenesis; Poole, UK) and FITC-labeled
Ulex europaeus agglutinin I (FITC-lectin, Sigma-
Aldrich). Cells were incubated with Dil-Ac-LDL (2.4 μg/
ml) for one hour at 37°C and fixed with 2% paraformal-
dehyde for 10 min. Cells were washed twice with DPBS
and then incubated with FITC-lectin (10 μg/ml) for one
hour at 37°C. Cells were washed twice with DPBS and
detached with 0.25% trypsin/EDTA.
FACS analysis
Before culturing the cells, the cEPCs were confirmed by
FACS with a PE-labeled monoclonal antibody against
human KDR (Genzyme Techne; Cambridge, MA), a
FITC-labeled monoclonal antibody against human
AC133 (Genzyme Techne), and a PerCP-labeled mono-
clonal antibody against human CD34 (Becton Dickin-
son). Then, 1.0 × 105 PBMCs were incubated with the
three antibodies for 30 min at 4°C in the dark. Isotype
antibodies were used as controls. After incubation, cells
were analyzed with a FACScan flow cytometer (Becton
Dickinson) and Cell Quest software (Becton Dickinson)
(Figure 1). On the 7th day of culture, adherent cells
were incubated with Dil-acLDL and FITC-lectin, and
double-stained cells were analyzed by FACS (Figure 2).
EPC culture with E2b or P4
To assess the effects of E2b or P4 on EPC proliferation
of EPCs, 8 × 105 PBMCs, derived from the peripheral
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blood of women in the menstrual or luteal phases, were
seeded into each well of 96-well culture plates coated
with human fibronectin (Sigma-Aldrich), and cultured
in endothelial basal medium (phenol red free EBM-2,
Clonetics; San Diego, CA) supplemented with EGM-
2MV (Clonetics) consisting of 5% charcoal stripped
serum (Invitrogen), VEGF, FGF2, EGF, IGF1, and ascor-
bic acid with or without 10-9-10-7 M of E2b or P4. ICI
182,780 (10-5 M, Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) or RU486 (10-5 M, Sigma-Aldrich) was
used as an inhibitor of ER or PR, respectively [26]. After
four days in culture, nonadherent cells were removed
and adherent cells were subsequently cultured for an
additional three days.
Isolation of RNA and semi-quantitative RT-PCR
Total RNA was collected from cells grown in 3.5 cm cell
culture dishes. Cells were washed with cold DPBS and sub-
sequently frozen at -80°C until isolation of total RNA. The
cells were disrupted and homogenized with an ultrasound
homogenizer. Total RNA was extracted using the RNeasy
Mini Kit (QIAGEN; Valencia, CA) according to the manu-
facturer’s instructions. Total RNA (2 μg) was reverse tran-
scribed to cDNA by incubating the samples with a random
primer (100 pmol/μl) at 70°C for 10 min, followed by 4°C
for 10 min. The samples were then incubated with Tris-
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 2.5
mM dNTPs, ribonuclease inhibitor (40 U/l Promega Corp.
Madison, WI), AMV reverse transcriptase XL (37 U/l
Takara Biochemicals Tokyo, Japan), and a dNTP mixture
(2.5 mM) and then incubated at 42°C for one hour. The
samples were subsequently heated at 99°C for 5 min to ter-
minate the reaction, and stored at 4°C.
ERa, ERb, progesterone receptor AB (PR AB), proges-
terone receptor B (PR B), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) oligonucleotide primers were
constructed from published nucleotide sequence databases
(Table 1). The level of GAPDH mRNA served as an inter-
nal standard for normalization of ER and PR mRNA levels.
RT-PCR conditions were optimized to ensure that amplifi-
cation proceeded within the linear portion of the reaction.
The semi-quantitative RT-PCR amplification profile con-
sisted of denaturation at 95°C for 3 min followed by 35
cycles of 95°C for 10 s and 65°C for 1 min.
The iQ SYBR Green Supermix (QIAGEN), 0.2 μM of
sense and antisense oligonucleotides (ER, PR, or
GAPDH), and 0.1 μg cDNA were used in a final volume
of 30 μl for each RT-PCR reaction. The PCR products
were digitally analyzed using a luminescent image analy-
zer (FluoImager, Beckton Dickinson) and quantified
using Image Quant software (Beckton Dickinson).
Statistical analysis
The results were expressed as mean ± standard error (SE).
Statistical analyses were performed by one-way analysis of
variance (ANOVA) followed by a post-hoc test (Bonfer-
roni). Statistical significance was determined as p < 0.05.
Results
Detection of cEPCs in peripheral blood during the
menstrual cycle
The number of cEPCs in the peripheral blood obtained
from subjects in the menstrual cycle was significantly
Figure 1 Characterization of circulating EPCs from peripheral
blood. A) The mononuclear cell fraction was selected based on low
granularity by forward and side scatter using FACS. B, C) Sorted cells
were fixed and immunostained with antibodies against human KDR,
AC133, and CD34, and then subjected to FACS analysis.
Figure 2 LDL/lectin assay to detect EPCs in culture . A)
Cultivated PBMCs were examined using Dil-Ac-LDL/FITC-lectin
uptake assays. B) Live EPCs exposed to Dil-AcLDL and C) stained
with FITC-lectin (Ulex europeaus) D) Merged images (40 × final
magnification).
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increased during the luteal (124.0 ± 29.1 cells/ml) and
menstrual (165.3 ± 38.5 cells/ml) phases compared to
the follicular phase (44.1 ± 11.1 cells/ml; p < 0.05; Fig-
ure 3A).
LDL/Lectin assay of cells cultured for seven days
The number of EPCs that were LDL+/lectin+ derived
from the peripheral blood of subjects in the luteal phase
was significantly increased on the seventh day of culture
(481.2 ± 91.2 cells/well) compared to the menstrual
phase (227.1 ± 26.5 cells/well; p < 0.05; Figure 3B).
Effects of E2b and P4 on the proliferation of EPCs in
peripheral blood
E2b or P4 significantly increased the proliferation of
EPCs derived from the peripheral blood of subjects in
the menstrual phase by activating the respective recep-
tors in a dose-dependent manner (Figure 4). Receptor
antagonists of ER and PR, ICI 182,780 and RU 486,
respectively, reduced the proliferation of EPCs from
menstrual phase. In addition, P4 did not influence the
effect of E2b on EPC proliferation. In contrast, the pro-
liferation of EPCs from luteal phase was not influenced
by E2b or P4 (Figure 5). Moreover, these receptor
antagonists did not affect the proliferation of EPCs from
luteal phase.
Change in ER and PR expression in cEPCs
ERa mRNA expression levels in EPCs from menstrual
phase were higher than ERb mRNA as well as ERa
mRNA in EPCs from luteal phase (p < 0.05; Figure 6).
In contrast, no significant difference was observed
between the expression level of total PR mRNA and iso-
form B mRNA in EPCs; however, the expression levels
of total PR mRNA and isoform B mRNA were limited
in EPCs (Figure 6).
Table 1 List of oligonucleotide primers used.
GeneBank accession No. mRNA Sequence Length of DNA
product (bp)
NM000125 ERa 5’ AAG AGC TGC CAG GCC TGC C 3’ (sense) 168
5’ TTG GCA GCT CTC ATG TCT CC 3’ (antisense)
AB006590.1 ERb 5’ TAA AAG AAG CAT TCA AGG ACA TAA T 3’ (sense) 160
5’ GCA CTT CTC TGT CTT CGT ACT ATT C 3’ (antisense)
AY382151 PR AB 5’ TGG AAG AAA TGA CTG CAT CG 3’ (sense) 196
5’ TAG GGC TTG GCT TTC ATT TG 3’ (antisense)
AB085683 PR B 5’ ACA CCT TGC CTG AAC TTT CG 3’ (sense) 196
5’ CTG TCC TTT TCT GGG GGA CT 3’ (antisense)
NM002046 GAPDH 5’ CCA CCC ATG GCA AAT TCC ATG GCA 3’ (sense) 622
5’ TCT AGA CGG CAG GTC AGG TCC ACC 3’ (antisense)
Figure 3 Changes in circulatory EPC proliferation during the menstrual cycle. A) The number of EPCs in peripheral blood. *: p < 0.05 vs.
the follicular phase. B) The proliferation of EPCs on the 7th day in culture. **: p < 0.05 vs. the luteal phase.
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Discussion
cEPCs in the peripheral blood serve as a reserve for EC
maintenance, and contribute up to 25% of ECs in newly
formed vessels of ischemic lesions [25,27-32]. In addi-
tion, estrogen preserves ischemic heart function during
myocardial infarction by augmenting the mobilization
and incorporation of bone marrow-derived EPCs into
sites of neovascularization [31]. In female reproductive
organs, EPCs appear to play a crucial role in vasculariza-
tion of the uterine endometrium at the site of embryo
Figure 5 The effect of E2b or P4 on the proliferation of EPCs from luteal phase. A) The effect of E2b on the proliferation of EPCs. B) The
effect of P4 on the EPCs proliferation.
Figure 4 Effects of E2b or P4 on the proliferation of EPCs from menstrual phase. A) The effect of E2b on the proliferation of EPCs. B) The
effect of P4 on the proliferation of EPCs. *: p < 0.05 vs. control.
#: p < 0.05 vs. cells treated with RU486.
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implantation and placentation [33-35]. During the men-
strual cycle, the number of cEPCs in peripheral blood
exhibits a cyclic change, whereby it is markedly
increased during the luteal and menstrual phase, and
decreased during the follicular phase. The number of
cEPCs has been shown to decrease over the course of
pregnancy [36]. Since EPCs were also found in the cor-
pus luteum and uterine endometrium, the estrogen-
mediated increase in EPCs is thought to be involved in
periodic neovascularization during the menstrual cycle
[28,37,38].
The differences in EPC proliferation and cEPC con-
centration between the menstrual and luteal phases
were the most important findings of this study. We
demonstrated that EPCs from menstrual phase did not
proliferate after seven days in culture; however, there
was a dose-dependent increase in proliferation after
cells were treated with E2b or P4. On the other hand,
proliferation was increased in EPCs from luteal phase
after seven days in culture; however, the proliferation
was not influenced by addition of E2b or P4. Therefore,
we hypothesize that luteal EPCs may have already
reached maximum stimulation in vivo and could not be
activated furtherer.
Decreased proliferation of EPCs from menstrual phase
suggests that this observed effect was due to decreased
concentration of E2b or P4 during menstruation. There-
fore, the increase in proliferation was a sex steroid-
mediated dose-dependent increase. Since the expression
of ERa and ERb in EPCs was different between the
menstrual and luteal phases, E2b-induced neovasculari-
zation may be mediated by both receptors, and the dif-
ferential expression of ERa and ERb indicates that they
have different effects on neovascularization. ERa mRNA
expression levels in EPCs from menstrual phase was
higher than those from luteal phase as shown in Figure
6. On the other hand, the ERb mRNA expression level
in EPCs from luteal phase was higher than ERa expres-
sion. Since estrogen-responsive element-dependent gene
transcription activities are severely impaired in EPCs
obtained from ERa-knockout mice, vascular growth is
down-regulated in ERa-knockout EPCs [39,40], and
epithelial cell proliferation can be reduced through the
activation of ERb [30], the increased expression of ERa
may at least partially explain the increase in E2b-induced
proliferation of EPCs derived from subjects in the men-
strual phase. However, the roles of ERa and ERb in
EPC biology during the menstrual cycle will require
further elucidation.
The cEPC concentration was lowest in the follicular
phase, and EPC proliferation in the cultures was not dif-
ferent compared to the other cultures. It has been well
established that the serum concentration of E2 and
VEGF is very low during the early follicular phase
[12,41]. Therefore, it is possible that decreased VEGF
and E2 expression during the follicular phase could
reduce the recruitment of cells from bone marrow into
blood, since VEGF can induce the recruitment of EPCs
from bone marrow [42]. These observations suggest that
the initial priming of the ovarian hormone is required
for EPC proliferation during the menstrual cycle.
Estrogen also stimulates extensive placental neovascu-
larization through the up-regulation of angiogenic fac-
tors in the uterus during pregnancy [43], and the
number of cEPCs peaks from luteal phase through the
1st trimester [44]. This finding is consistent with the
fact that vasculogenesis peaks during embryogenesis
[35,45]. On the other hand, estrogen is reduced after
menopause, which leads to the depletion of EPCs [38],
and estrogen replacement therapy can delay the onset of
senescence in bone marrow-derived EPCs [46]. There-
fore, estrogen is critical in promoting angiogenesis and
vasculogenesis in female reproductive organs.
Conclusion
In the female reproductive system, vasculogenesis is a
recurring phenomenon controlled by the cyclical devel-
opment of a transient structure and the cyclical repair
of damaged tissue by E2 and P4 during the menstrual
cycle. It is hypothesized that neovascularization is regu-
lated by the crosstalk between these hormones in utero
during the ovarian cycle and pregnancy in preparation
for implantation and the maintenance of pregnancy.
The findings described in this study provide evidence
that the physiologic cycle of estrogen regulates EPC pro-
liferation through the alternating balance of ER mRNA
expression.
Figure 6 Expression of ER and PR mRNA in circulating EPCs.
ERa, ERb, and PR mRNA expression in EPCs derived from peripheral
blood during the menstrual cycle (menstrual phase: solid column,
luteal phase: open column). *: p < 0.05 vs. the expression of ERa in
EPCs from menstrual phase.
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